Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895722 | 0.82 | KCNA5 (0.38) | ALOX5RORC | |
| SCHEMBL17895688 | 0.81 | PIK3CG (0.38) | ALOX5PIK3CAPIK3CG | |
| SCHEMBL17895701 | 0.81 | TUBB4A (0.36) | ALOX5PIK3CAPIK3CG | |
| SCHEMBL17895619 | 0.78 | CASR (0.36) | ALOX5PDE5APDE4DPDE7A | |
| SCHEMBL17895704 | 0.77 | PDE5A (0.34) | ALOX5PDE5APDE4DPDE7A | |
| SCHEMBL17895666 | 0.77 | APP (0.38) | PIK3CAPIK3CG | |
| SCHEMBL17895580 | 0.73 | ALOX5 (0.33) | ALOX5PDE5APDE4DPDE7A | |
| SCHEMBL17895600 | 0.73 | DYRK1A (0.34) | ALOX5PDE5APDE4DPDE7APIK3CA | |
| SCHEMBL17895649 | 0.73 | ALOX5 (0.33) | ALOX5PDE5APDE4DPDE7A | |
| SCHEMBL17895680 | 0.72 | ALOX5 (0.32) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | claimed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | claimed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851095-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | ALOX5 158/4885PDE5A 68/4885PDE4D 337/4885 |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | ALOX5 158/4885PDE5A 68/4885PDE4D 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.